M&A news

Biographica Acquires Bayer, Strengthening

Bayer acquired by Biographica

AcquisitionDE

Get the full Bayer company profile

Access contacts, investors, buying signals & more

Open in Dashboard
Bayer logo
Acquired

Bayer

Germany

Undisclosed amount

January 18, 2026

Biographica logo
Acquirer

Biographica

Farming, Ranching, Forestry

Biographica has acquired Bayer, the global enterprise with core competencies in the life science fields of healthcare and nutrition, for an undisclosed amount. This strategic acquisition marks a significant expansion for Biographica into critical sectors addressing essential human needs. Bayer has long focused on designing its products and services to serve the most fundamental human requirements of health and nutrition, while also actively working to address some of the world’s biggest challenges presented by a growing and aging global population.

Bayer's deep commitment to driving sustainable development and generating a positive impact with its businesses aligns with a forward-looking vision for the combined entity. Through the power of science, Bayer has pioneered new possibilities that advance life for all, reimagining how care is delivered by empowering everyday health, improving approaches to patient care, and finding better ways to nourish communities around the world. This established expertise in healthcare and nutrition provides Biographica with a robust platform for growth and innovation within the life sciences sector.

The acquisition is expected to create substantial synergies by integrating Bayer's extensive research and development capabilities, global operational footprint, and deep market understanding into Biographica's strategic framework. By bringing Bayer's focus on essential human needs and sustainable development under its umbrella, Biographica aims to significantly strengthen its position in the life sciences sector. This move is poised to enhance the development and delivery of solutions that address pressing global health and nutrition challenges, leveraging Bayer's scientific advancements and established market presence.

The combined entity is anticipated to accelerate innovation across healthcare and nutrition, driving progress in areas vital for a thriving global population. This integration is set to foster new opportunities for scientific discovery and market expansion, ultimately aiming to deliver enhanced value to stakeholders and contribute to improved well-being worldwide through a unified approach.

No buying signals identified yet.

Unlock GTM signals

Discover Bayer's tech stack and active buying intent.

View GTM signals

Unlock key decision-makers

Get direct access to the decision-makers at Bayer.

Unlock decision-makers